Suzana Brozovic, MD
Gastroenterology · Crestview Hills, KYNPI 1225216989
Payments from drug & device makers
Across 94 payments — averaging $16.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$403
- AbbVie$225
- Takeda Pharmaceuticals U.S.A., Inc.$129
- Sanofi$88
- Daiichi Sankyo Inc.$82
- Gilead$78
- plus $570 from 19 others
What the payments were for
- Consulting fees$161%
- Food & beverage$1,54798%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 23 | $403 |
| AbbVie | 14 | $225 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $129 |
| Sanofi | 5 | $88 |
| Daiichi Sankyo Inc. | 4 | $82 |
| Gilead | 5 | $78 |
| QOL Medical, LLC | 4 | $65 |
| Ironwood Pharmaceuticals, Inc | 4 | $59 |
| Bristol Myers Squibb | 3 | $54 |
| Micro-tech Endoscopy USA, Inc. | 3 | $49 |
| Pfizer | 3 | $47 |
| Madrigal Pharmaceuticals | 1 | $34 |
| Nestle Healthcare Nutrition Inc. | 2 | $31 |
| Johnson & Johnson(2 entities) | 2 | $29 |
| Evoke Pharma, Inc. | 2 | $27 |
| Medtronic | 1 | $26 |
| Ferring Pharmaceuticals Inc. | 1 | $21 |
| Celltrion USA Inc. | 1 | $21 |
| Amgen | 1 | $18 |
| Novo Nordisk | 1 | $17 |
| Redhill Biopharma Inc. | 1 | $16 |
| Intercept Pharmaceuticals, Inc. | 1 | $16 |
| Braintree Laboratories, Inc. | 1 | $15 |
| Merck | 1 | $14 |
| Boston Scientific | 1 | $12 |
How this compares
$1,574 in reported general payments places this provider in the 30th percentile of 207 gastroenterology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 39 | $123,515 |
| XeljanzTofacitinib Citrate | 13 | $66,499 |
| CreonLipase/Protease/Amylase | 35 | $62,976 |
| LinzessLinaclotide | 61 | $42,484 |
| RelistorMethylnaltrexone Bromide | 17 | $38,668 |
| MovantikNaloxegol Oxalate | 51 | $30,060 |
| Mesalamine | 29 | $9,554 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 121 | $8,034 |
| Dexlansoprazole DrDexlansoprazole | 18 | $6,043 |
| Sucralfate | 29 | $4,436 |
| Pantoprazole Sodium | 354 | $4,166 |
| Ursodiol | 18 | $3,234 |
| Esomeprazole Magnesium | 56 | $1,498 |
| Omeprazole | 125 | $1,369 |
| Dicyclomine Hcl | 33 | $1,311 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Relistor | $403 | $162,18356 claims |
| AbbVieCreon, Linzess | $225 | $105,46096 claims |
| PfizerXeljanz | $47 | $66,49913 claims |
| Redhill Biopharma Inc.Movantik | $16 | $30,06051 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 207 gastroenterology providers in Kentucky.
Other gastroenterology in Crestview Hills
- Michael JonesCrestview Hills$1.9M
- Zahid SaeedCrestview Hills$442K
- Joel WarrenCrestview Hills$13K
- Chadwick HatfieldCrestview Hills$13K
- Karlina PattonCrestview Hills$11K
- Daniel FagelCrestview Hills$10K
- Scott LeverageCrestview Hills$10K
- Gerald DrydenLouisville$3.5M
- Jens RosenauLexington$1.6M
- Matthew CaveLouisville$916K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.